New Non-Opioid Painkiller Shows Promise in Outperforming Traditional Opioids

Researchers at Duke University have developed an innovative pain relief drug, SBI-810, which could revolutionize pain management by providing effective relief without the risks associated with opioids. Unlike conventional opioids that activate multiple cellular pathways, SBI-810 specifically targets a receptor in the nervous system linked to pain sensation, avoiding the euphoric effects that lead to addiction. In preclinical studies involving mice, SBI-810 demonstrated notable success by alleviating pain from various sources such as surgical incisions, bone fractures, and nerve injuries. Notably, it outperformed some existing painkillers like gabapentin and showed better efficacy than opioids in certain cases, without causing tolerance or sedation.

The drug works by activating the neurotensin receptor 1 through a mechanism called biased agonism, selectively engaging signals that produce pain relief while sidestepping pathways that result in side effects. This targeted approach holds promise for both acute and chronic pain conditions, including postoperative pain and diabetic nerve pain. Researchers reported that SBI-810 effectively reduced signs of discomfort in animal models, such as guarding and facial grimacing, and did not induce common opioid-related issues like tolerance or constipation.

Despite being in early stages of development, Duke scientists are optimistic about advancing SBI-810 into human trials soon, having secured multiple patents for their discovery. The need for safer pain management options is urgent, especially considering that more than 80,000 Americans die annually from opioid overdoses, in addition to the widespread prevalence of chronic pain affecting a large portion of the population. The specificity of SBI-810's action could make it a safer alternative for managing pain in post-surgical recovery, diabetic nerve pain, and other conditions, offering effective relief while minimizing risks of addiction and side effects.

This breakthrough highlights a promising direction in pain medicine—leveraging targeted receptor activation to provide powerful, safe, and non-addictive pain relief options.

source: https://medicalxpress.com/news/2025-05-experimental-painkiller-outsmart-opioids-high.html